Conversations with commerical payers about reimbursement mechancisms is a next step, says rearcher Kathi Mooney.
Women who get a genetic testing for hereditary breast and ovarian cancer are often advised to talk to a genetic counselor before and after they take the test, even if the result is negative for a mutation that would indicate a greater ris
Flatiron Health’s Dr. Bobby Green Outlines Novel Clinical Trial to Understand Genomic Changes in Tumors (VIDEO)
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech will be presenting plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.
Ten of thousands of oncologists flock to the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago every year to hear about new drugs. Even preliminary or incremental developments can excite the crowd.
Managed Healthcare Executive recently had a wide-ranging conversation with de Brantes about COVID-19, the healthcare sector and how the precipitous drops in utilization and provider revenue may affect the future of bundled payment and other alternative payment models.
Anna Lee, lead author of the abstract: Changes in Cancer Mortality Rates After the Adoption of the Affordable Care Act, discusses her study with MHE. Lee presented her study May 29 during ASCO 2020's virtual conference.
Sara Douglas, lead investigator of the Abstract: Video Conference Intervention for Distance Caregivers (DCGs) of Patients with Cancer: Improving Psychological Outcomes, discusses her study with MHE's Briana Contreras which will be presented at ASCO 2020.
A fresh look at MURANO data, released this week at the American Society of Clinical Oncology 2020 Annual meeting, shows the poor outcomes that result when patients halt treatment for good, and highlight the need to manage doses carefully to avoid toxicity.
The 2020 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1).
ASCO Report: Hydroxychloroiquine, Azithromycin Combo Associated With Mortality Risk Among Cancer Patients
Researchers caution, though, that the association may be of uncertain validity because of residual confounding.